Tonix Pharmaceuticals Holding Corp. (TNXP) intrinsic value & 10-year financials
Tonix Pharmaceuticals Holding Corp. (TNXP) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 29.9% a year to $13.1M, with an average return on invested capital of -90.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $6.04
- Market cap
- $51.4M
- Revenue (FY2025)
- $13.1M
- Revenue growth (10-yr CAGR)
- 29.9%
- ROIC (10-yr avg)
- -90.0%
- Free cash flow (FY2025)
- -$103.2M
TNXP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $13.1M | -$124.0M | -$14.57 | -$103.2M | -959.1% | -284.0% |
| FY2024 | $10.1M | -$130.0M | -$14.72 | -$61.0M | -1354.3% | -187.4% |
| FY2023 | $7.8M | -$116.7M | -$0.57 | -$109.9M | -1523.9% | -131.5% |
| FY2022 | — | -$110.2M | -$0.27 | -$146.2M | — | -172.5% |
| FY2021 | — | -$92.3M | -$0.22 | -$110.9M | — | -356.2% |
| FY2020 | — | -$50.5M | — | -$57.1M | — | -1065.7% |
| FY2019 | — | -$28.6M | — | -$26.7M | — | 1567.3% |
| FY2018 | — | -$26.1M | — | -$24.0M | — | — |
| FY2017 | — | -$21.1M | — | -$19.1M | — | — |
| FY2016 | — | -$38.8M | — | -$37.4M | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Tonix Pharmaceuticals Holding Corp. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Tonix Pharmaceuticals Holding Corp. has historically struggled to out-earn its cost of capital, averaging just -19.5% ROIC.
Tonix Pharmaceuticals Holding Corp. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Tonix Pharmaceuticals Holding Corp. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-483.95 per share.